Establishment of a GDUFA-Based Research Center for Complex Generics

The U.S. Food and Drug Administration (FDA) is investing a total of $5 million over five years in the University of Maryland School of Pharmacy and the University of Michigan College of Pharmacy to address the chronic regulatory bottlenecks in the complex generics market. This initiative, supported by the Generic Drug User Fee Act (GDUFA) regulatory science program, aims to proactively establish a Collaborative Research Center for Generics (CRCG). Complex drugs, such as liposome injections or modified-release inhalation products, pose challenges in demonstrating bioequivalence, creating significant barriers to entry for follow-on drug development.

The FDA is demonstrating a strong commitment to go beyond simply funding research and to establish clear standards for drug equivalence assessment through collaborative research.

Establishing Technical Equivalence Standards for a $98 Billion Market

The global complex generics market is estimated at approximately $98 billion by 2026 and is considered a high-growth area as original patents expire. Researchers at the University of Maryland and the University of Michigan will use advanced analytical techniques and computer simulation modeling to standardize the chemical and biological characteristics of complex formulations. By proactively building a shared database of toxicology and release characteristic data, they aim to quantify the process of verifying the homogeneity of complex formulations. This enhancement of regulatory science is expected to be a key factor in significantly shortening the review time for abbreviated new drug applications (ANDAs).

Enhancing Predictability for Biotech and Follow-on Pharmaceutical Companies

The establishment of this research center will greatly contribute to reducing the significant regulatory uncertainty faced by small and medium-sized biotech and generic manufacturers. Even when developing innovative complex generics to compete with blockbuster original drugs from multinational corporations with proprietary technologies, approvals have often been delayed due to the lack of guidelines for demonstrating equivalence. The open workshops and standard guidelines provided by the CRCG will enable manufacturers to reduce the risk of Complete Response Letters (CRLs) and significantly reduce development costs. As a result, companies with strong technological capabilities will be able to accelerate their market entry.

Regulatory Innovation Leading to Lower Drug Prices and Stable Medical Supply Chains

The FDA's proactive approach aligns with its policy goals of eliminating the monopoly of high-priced patented drugs and significantly expanding patient access to medicines. The entry of competitive follow-on drugs in complex formulation areas such as peptide formulations or drug-device combinations is expected to intensify pressure to lower drug prices. It will also help improve the imbalance in the supply of drugs for rare diseases and promote the stability of the global pharmaceutical supply chain. Ultimately, a virtuous cycle ecosystem will be created through collaboration between research institutions, regulatory authorities, and the pharmaceutical industry, leading to positive effects that expand the overall market.